Jennifer Pietenpol named chief scientific advisor for Susan G. Komen

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Jennifer Pietenpol, executive vice president for research at Vanderbilt University Medical Center and director of Vanderbilt-Ingram Cancer Center, was named a chief scientific advisor for the nonprofit breast cancer organization Susan G. Komen.

She joins George Sledge Jr., professor of Medicine at Stanford University Medical Center, in the CSA role, which includes responsibility for guiding the Komen Scientific Advisory Board.

The scientific advisory board helps guide Komen’s research programs and priorities. Since 2010, Pietenpol has served as a Komen Scholar, an advisory group of distinguished leaders in breast cancer research and advocacy who are chosen for their knowledge and leadership within the scientific, research and advocacy communities, and for their own contributions to breast cancer research.

Pietenpol, the Benjamin F. Byrd Jr. Professor of Oncology at Vanderbilt, is an expert in molecular genetics and triple negative breast cancer. She and her colleagues were the first to identify subtypes of TNBC and are spearheading clinical research trials to determine the best potential therapies for each subtype.

YOU MAY BE INTERESTED IN

If you listen to GRAIL executives discuss the results of the long-awaited trial of the company’s multicancer detection test, you might be led to conclude that the company’s pivotal NHS-Galleri study had an overwhelmingly positive result.
Undeterred by the negative topline result of its pivotal trial of Galleri, a multicancer detection test, the test’s sponsor, GRAIL, said it’s forging ahead with its plan to get FDA approval and reimbursement from CMS and private insurers.
Philip E. Castle, director of the NCI Division of Cancer Prevention, said he was disappointed to hear that GRAIL’s NHS-Galleri trial did not meet its primary endpoint of reduction in late-stage cancers.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login